Skip to main content
ToolsForensic Analysisbarrs pharmaceuticals industries

barrs pharmaceuticals industries

Supplier Forensic Analysis · Scanned: 2026/05/23

Disclaimer: Statistical patterns flagged for review only. This tool does not determine or imply wrongdoing. All findings require independent verification.
Risk Score
Forensic risk score: 0 out of 100. LOW RISK.Forensic risk score: 0 out of 100. LOW RISK.
0RISK SCORE
LOW RISK
Compliance
N/A/100
Awards
4
Total Value
R 2B

Recent Awards

4 awards · Total: R 1 984 260 834

Showing 5 of 4
HP02-2025AI: Supply and Delivery of Anti-Infective Medicines (Antibiotics, Antifungal, Antiprotozoal and Antiviral Agents) to the Department of Health for the period 1 October 2025 to 30 September 2028.
Health
Ref: HP02-2025AI
R 36 876 187
21 Aug 2025
HP13-2025ARV: Supply and Delivery of Anti-Retroviral Medicines to the Department of Health for the period 1 July 2025 to 30 June 2028
Health
Ref: HP13-2025ARV
R 1 781 936 369
20 Aug 2025
Supply and Delivery of Anti-Infective Medicines (Antibiotics, Antifungal, Antiprotozoal and Antiviral Agents) to the Department of Health for the period 1 October 2023 to 30 September 2025
Health
Ref: HP02-2023AI
R 11 640 120
15 Jun 2023
SUPPLY AND DELIVERY OF SEMI-SOLID DOSAGE FORMS AND POWDERS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 JULY 2023 TO 30 JUNE 2026 ERRATUM 1: PLEASE NOTE THAT THE SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT (SRCC) AS PUBLISHED WITH THE BID PACK ON 17 JUNE 2022 FOR TENDER HP08-2023SSP IS BEING REPLACED WITH THIS ERRATUM.
Health
Ref: HP08-2023SSP
R 153 808 158
13 Feb 2023

AI Analysis

Powered by Gemini

AI Forensic Analysis

Get AI-generated audit narratives with key findings and recommended actions.
Paid access from R499/mo

or upgrade to Pro Subscription

Risk Assessment

Forensic risk score: 0 out of 100. LOW RISK.Forensic risk score: 0 out of 100. LOW RISK.
0RISK SCORE
LOW RISK

Based on 0 forensic flags detected

Unlock Full Analysis

Get access to all forensic flags, evidence details, and AI-generated audit narratives.

View Full Intelligence Report

Get complete award history, director network, and compliance analysis.

View Report →